|
Press Releases |
|
|
|
Wednesday, September 8, 2021 |
|
阿诺医药宣布AN2025、AN0025与atezolizumab三联治疗晚期实体瘤1a期临床在美国完成首例患者给药 |
阿诺医药,一家专注于肿瘤治疗领域的创新型全球生物制药公司,今日宣布其口服泛PI3K抑制剂buparlisib(AN2025)、口服EP4拮抗剂(AN0025)与PD-L1抑制剂atezolizumab(阿替利珠单抗)三联疗法在晚期/转移性实体瘤患者中开展的Ia期临床试验已于美国成功完成首例患者给药。 more info >> |
|
阿諾醫藥宣佈AN2025、AN0025與atezolizumab三聯治療晚期實體瘤1a期臨床在美國完成首例患者給藥 |
阿諾醫藥,一家專注於腫瘤治療領域的創新型全球生物製藥公司,今日宣佈其口服泛PI3K抑制劑buparlisib(AN2025)、口服EP4拮抗劑(AN0025)與PD-L1抑制劑atezolizumab(阿替利珠單抗)三聯療法在晚期/轉移性實體瘤患者中開展的Ia期臨床試驗已于美國成功完成首例患者給藥。 more info >> |
|
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors |
Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple combination of AN2025 (buparlisib, oral pan-PI3K inhibitor), AN0025 (oral EP4 antagonist) and atezolizumab (PD-L1 inhibitor) in patients with locally advanced/metastatic tumors. more info >> |
|
Thursday, July 15, 2021 |
|
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures |
Adlai Nortye Ltd. (hereinafter referred to as "Adlai Nortye"), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced the completion of $100 million Series D financing round. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Masverse Unveils Groundbreaking Blockchain Platform
Apr 27, 2024 02:40 HKT/SGT
|
|
|
Spritzer Scores Big with 'Meet the Red Legends' Event for Football Fans
Apr 26, 2024 23:00 HKT/SGT
|
|
|
Announcing Mad About Marketing - A New Member of the Digital Sukoon Private Limited Family
Apr 26, 2024 22:25 HKT/SGT
|
|
|
FinTech Funding Continues to Surge as Second Edition of Dubai FinTech Summit Commences
Apr 26, 2024 21:10 HKT/SGT
|
|
|
汇聚科技有限公司公布截至二零二三年十二月三十一日止末期业绩
Apr 26, 2024 18:53 HKT/SGT
|
|
|
匯聚科技有限公司公佈截至二零二三年十二月三十一日止末期業績
Apr 26, 2024 18:43 HKT/SGT
|
|
|
UK advertising reports GBP36.6bn spend in 2023
Apr 26, 2024 18:30: JST
|
|
|
TIME Interconnect Technology Limited Announces Final Results For The Nine Months Ended 31 December 2023
Apr 26, 2024 18:26 HKT/SGT
|
|
|
UK advertising reports GBP36.6bn spend in 2023
Apr 26, 2024 17:30 HKT/SGT
|
|
|
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine
Apr 26, 2024 15:36 HKT/SGT
|
|
|
可持续发展三大支柱引领 海通恒信ESG必答卷高分亮相
Apr 26, 2024 15:28 HKT/SGT
|
|
|
可持續發展三大支柱引領 海通恆信ESG必答卷高分亮相
Apr 26, 2024 15:25 HKT/SGT
|
|
|
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project
Apr 26, 2024 14:34: JST
|
|
|
スパークス・グループによる「宇宙フロンティア2号ファンド」の設立について
Apr 26, 2024 14:00: JST
|
|
|
中滙集團公佈2024財年中期業績
Apr 26, 2024 13:51 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|